摘要
目的探讨齐拉西酮与氟哌啶醇治疗脑血管病所致精神障碍的疗效及安全性。方法将68例脑血管病所致精神障碍患者分为研究组和治疗组,每组34例,在神经内科常规治疗的基础上,研究组口服齐拉西酮,对照组口服氟哌啶醇,观察6周。在治疗前和治疗第2、4、6周末,分别采用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)评定疗效及不良反应。结果治疗6周末,研究组有效率91.2%,对照组为85.3%,2组比较差异无统计学意义(P>0.05);随着治疗的延续,PANSS总分及各因子分均较治疗前显著下降(P<0.05或0.01);同期比较2组比较差异无统计学意义(P>0.05);2组不良反应均较轻,研究组主要表现为体位性低血压、嗜睡等,对照组主要表现为肌强直、便秘等。结论齐拉西酮治疗脑血管病所致精神障碍疗效显著,与氟哌啶醇相当,安全性高,依从性好。
Objective To explore the clinical efficacy and safety of ziprasidone in the treatment of mental disorders due to cerebrovascular disease（MDCD）. Methods Sixty-eight MDCD were randomly divided into two groups,34 patients in each group,respectively took ziprasidone and haloperidol for 6 weeks.The both groups were assessed by the positive and negative syndrome scale（PANSS）,and side effects scale（TESS）respectively before treatment and after treatment of 2,4,6 weeks. Results After 6-week treatment,the effective rate of study group was 91.2% and that of control group was 85.3%,there was no significant difference between the two groups（ P 0.05）.Since the end of second week,PANSS total scores and each factor score were significantly decreased compared with that before treatment（ P 0.05 or 0.01）;Over the same period,the scores of both two groups showed no significant difference（ P 0.05）.The adverse reactions were all minor,the postural hypotension,lethargy and so on were mainly in study group,and myotonia,constipation ect in the control group. Conclusion The effect of ziprasidone and haloperidol in the treatment of MDCD is quite,and has higher safety and better compliance.
出处
《中国实用神经疾病杂志》
2012年第12期10-12,共3页
Chinese Journal of Practical Nervous Diseases
关键词
脑血管病所致精神障碍
齐拉西酮
氟哌啶醇
Mental disorders due to cerebrovascular disease
Ziprasidone
Haloperidol
